Sun unit resolves antitrust lawsuit for $485m
24-03-2022
Intubated patients sedative patent the focus of ACS Dobfar suit
16-12-2021
Jazz Pharma accused of pay-for-delay deals over Xyrem
14-10-2021
Pavel Kapysh / Shutterstock.com
Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sun Pharma, Ranbaxy, competition, antitrust, anti-competitive, generics, ANDAs
